Oligodeoxynucleotide inhibitors of function: mRNA and protein interactions

Cancer Journal from Scientific American

Volumn 4, Issue SUPPL. 1, 1998, Pages

  Neckers, Leonard M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN;

ARTICLE; CANCER RESEARCH; DRUG EFFECT; DRUG RESEARCH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031843324     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Weintraub HM. Antisense RNA and DNA. Sci Am 1990;262: 40-46.
2. Inouye M. Antisense RNA: its functions and applications in gene regulation - a review. Gene 1988;72:25-34.
3. Kochbin S, Lawrence JJ. An antisense RNA involved in p53 mRNA maturation in murine erythroleukemia cells induced to differentiate. EMBO J 1989;8:4107-4114.
4. Krystal GW, Armstrong BC, Battey JF. N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts. Mol Cell Biol 1990;10:4180-4191.
5. Izant JG, Weintraub H. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science 1985;229:345-352.
6. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-284.
7. Izant JG, Weintraub H. Inhibition of thymidine kinase gene expression by antisense RNA: a molecular approach to genetic analyses. Cell 1984;36:1007-1015.
8. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994;4:67-69.
9. Woolf TM, Melton DA, Jennings CGB. Specificity of antisense oligonucleotides in vivo. Proc Nad Acad Sci USA 1992;89:7305-7309.
10. Chang EH, Miller PS, Cushman C et al. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 1991;30:8283-8286.
11. Kuramoto E, Yano O, Kimura Y et al. Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 1992; 83:1128-1131.
12. Yamamoto S, Yamamoto T, Kataoka T et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J Immunol 1992;148:4072-4076.
13. Tokunaga T, Yano O, Kuramoto E et al. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol 1992;36:55-66.
14. Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis GCG. I. Isolation, physicochemical characterization, and antitumor activity. J Nad Cancer Inst 1984;72:955-962.
15. Shimada S, Yano O, Inoue H et al. Antitumor activity of DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J Natl Cancer Inst 1985;74:681-688.
16. Krieg AM, Yi A-K, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
17. McIntyre KW, Lombard-Gillooly K, Perez JR et al. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation. Antisense Res Dev 1993;3:309-322.
18. Ballas Z, Rasmussen W, Krieg A. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996;157:1840-1845.
19. Klinman DM, Yi AK, Beaucage SL et al: CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete intetleukin-6, interleukin-12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879-1883.
20. Yi AK, Chace JH, Cowdery JS et al. Interferon-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 1996;156:558-564.
21. Blagosklonny MV, Neckers LM. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs. Anticancer Drugs 1994;5:437-442.
22. Stull RA, Zon G, Szoka FC. Single-stranded phosphodiester and phosphorothioate oligonucleotides bind actinomycin D and interfere with tumor necrosis factor-induced lyis in the L929 cytotoxicity assay. Antisense Res Dev 1993:3:295-300.
23. Wadkins RM, Jovin TM. Actinomycin D and 7-aminoactinomycin D binding to single-stranded DNA. Biochemistry 1991; 30:9469-9478.
24. Nickers L, Whitesell L, Rosolen A et al. Antisense inhibition of gene expression. Grit Rev Oncog 1992;3:175-231.
25. Whitesell L, Geselwitz D, Chavany C et al. Stability, clearance and disposition of intraventricularly administered oligodeoxynucleotides - implications for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 1993;90:4665-4669.
26. Ogawa S, Brown HE, Okano HJ et al. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul Pept 1995;59:143-149.
27. Akhtar S, Kole R, Juliano RL. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci 1991; 49:1793-1801.
28. Iverson PL, Zhu S, Meyer A et al. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 1992;2:211-222.
29. Campbell JM, Bacon TA, Wickstron E. Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, serum and cerebrospinal fluid. J Biochem Biophys Methods 1990; 20:259-267.
30. Cazanave C, Stein CA, Loreau N et al. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res 1989;17:4255-4273.
31. Wellstein A, Zugmaier G, Califano J et al. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Nad Cancer Inst 1991;83:716-720.
32. Zugmaier G, Lippman M, Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor cell growth in animals. J Natl Cancer Inst 1993;84:1716-1724.
33. Yakubov L, Khaled Z, Zhang L et al. Mode of interaction of oligodeoxynucleotides with recombinant sCD4. J Biol Chem 1993;268:18818-18823.
34. Maury G, Alaoui AE, Morvan F et al. Template-phosphorothioate oligonucleotide duplexes as inhibitors of HIV-1 reverse transcriptase. Biochem Biophys Res Commun 1992;186:1249-1256.
35. Stein CA, Cleary A, Yakubov L et al. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (V3) of HIV-1 gp120. Antisense Res Dev 1993;3:19-31.
36. Gao W-Y, Han F-S, Storm C et al. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1992;41:223-229.
37. Stein CA, Tonkinson JL, Zhang L-M et al. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 1993;332:4855-4861.
38. Perez JR, Li Y, Stein CA et al: Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Nad Acad Sci USA 1994;91:5957-5961.
39. Teasdale RM, Matson SJ, Fisher E et al. Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. Antisense Res Dev 1994;4:295-297.
40. bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994;22:2150-2154.
41. Bergan RC, Lyle E, Connell Y et al. Inhibition of protein tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev 1995;5:33-38.
42. Bock LC, Griffin LC, Latham JA et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355:564-566.
43. Watson PH, Pon RT, Shiu RPC. Inhibition of cell adhesion to plastic substratum by phosphorothioate oligonucleotide. Exp Cell Res 1992;202:391-397.
44. Yaswen P, Stampfer MR, Ghosh K et al. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993:67-77.
45. Maltese J-Y, Sharma HW, Vassilev L et al. Sequence context of antisense RelA/NF-KB phosphorothioates determines specificity. Nucleic Acids Res 1995;23:1146-1151.
46. Chavany C, Connell Y, Neckers L. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 1995; 48:738-746.
47. Brown DA, Kang SH, Gryaznov SM et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994;269:26801-26805.
48. bcr-abl tyrosine kinase activity [abstr]. Biol Blood Bone Marrow Transplant 1996;2:152.
49. Bergan R, Hakim F, Schwartz G et al. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996;88:731-741.
50. Wooldridge J, Ballas Z, Krieg A et al. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997;89:2994-2998.
51. Weiner G, Lir H, Wooldridge J et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-10837.
52. Griffin LC, Tidmarsh GF, Bock LC et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993;81:3271-3276.
53. Macaya RF, Schmultze P, Smith FW et al. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA 1993;90:3745-3749.
54. Wyatt JR, Vickers TA, Roberson JL et al. G-quartet structure is a potent inhibitor of HIV envelope-mediated cell fusion. Proc Natl Acad Sci USA 1994:91:1356-1360.
55. Buckheit RW, Roberson JL, Lackman-Smith C et al. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). Antisense Res Dev 1994;10:1497-1506.